Skip to Content

Wegovy FDA Approval History

Last updated by Judith Stewart, BPharm on June 8, 2021.

FDA Approved: Yes (First approved June 4, 2021)
Brand name: Wegovy
Generic name: semaglutide
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Obesity

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are overweight (BMI ≥27 kg/m2) or obese (BMI ≥30 kg/m2).

Development Timeline for Wegovy

Jun  4, 2021Approval  FDA Approves Wegovy (semaglutide) to Treat Adults with Obesity
Mar 23, 2021Adults with Obesity Treated with Semaglutide 2.4 mg Achieved and Maintained a Significant Amount of Weight Loss in a 68-Week Trial

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.